Korecyte Bio presented its ambitions within the CAR-T field at the CAR-TCR Summit 2024 in London. These three days were packed with excellent talks, discussions networking with peers. On Thursday February 29th, Korecyte’s CSO Dr. James Arnold presented our technology at the 7th CAR-TCR Summit. The talk showcased the strength of Korecyte’s HypoxiCAR platform switching technology that can render CAR-based cell therapy approaches safer and better equipped to combat solid tumours. It was an absolute honour for our CSO to chair an innovation session that involved some excellent speakers.